Trospium

Trospium has been studied in 5 papers since 2021: 5 observational studies in people; 1 in the past year. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

Intervention

5 papers study it4 more mention it1 findingUpdated Nov 6, 2026

PubChem ChEBI

1 new paper in 30 daysSee all 9 papers on trospium

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 21 trials, none about aging, 1 with no results posted.

1 lab in 1 country
21 trials, none about aging, 1 with no results posted

18 of 21 trials sponsored by its developers

Humans5

What did studies of trospium find?

Studies of trospium measured 1 outcome; the most studied are dementia (1 study).

Dementia

no changein humans1

1 study

Trospium was not clearly linked with dementia in humans.
“no increased risk for trospium”
Humans
Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database
The Journal of urologyJun 10, 2022

Who is developing trospium?

2 companies: Bristol-Myers Squibb and Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Companies: Bristol-Myers SquibbPhase 3bipolar disorder type i with mania, bipolar i disorder with mania or mania with mixed features
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 1

Trial sponsors

Allergan
Company2 trialsPhase 464 people
Bristol Myers Squibb
Company5 trialsPhase 31,899 people
Karuna Therapeutics
Company4 trialsPhase 3745 people
University of Texas Medical Branch
1 trialEarly phase 148 people

Latest

1 paper in 12 months

JAMA Network OpenNov 6

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia